XML 71 R63.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details) € in Thousands | 1 Months Ended | 6 Months Ended
--- | --- | ---
Mar. 31, 2023 EUR (€) target_option | Jun. 30, 2024 EUR (€) preclinicalMolecule | Jun. 30, 2023 EUR (€)
Agreement with Sanofi, 2022 |  |  |
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Payments for target options | € 5,000 |  |
Number of target options | target_option | 2 |  |
Payments for research work | € 1,500 |  |
Agreements with Sanofi for NK Cell engages |  |  |
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Payments for target options |  | € 5,000 |
Number of target options | target_option | 2 |  |
Number of preclinical molecules | preclinicalMolecule |  | 2 |
Revenues from contract liabilities, period |  | 3 years |
Payments for research work | € 1,700 | € 1,500 |
Deferred revenue |  |  |
Deferred Revenue, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 10,481 | € 14,481
Revenue for the six months period/Deductions |  | (3,396) | (9,675)
Contract liabilities at end of period |  | 6,915 | 11,024
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 10,481 | 14,481
Contract liabilities at end of period |  | 6,915 | 11,024
Deferred revenue | 2015 monalizumab agreement, with AstraZeneca |  |  |
Deferred Revenue, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 5,156 | 14,481
Revenue for the six months period/Deductions |  | (2,994) | (9,503)
Transfer from / (to) collaboration liabilities |  | (172) | (283)
Contract liabilities at end of period |  | 1,990 | 4,695
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 5,156 | 14,481
Contract liabilities at end of period |  | 1,990 | 4,695
Deferred revenue | Agreement with Sanofi, 2022 |  |  |
Deferred Revenue, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 5,327 | 0
Increase in deferred revenue/Additions |  | 0 | 6,500
Revenue for the six months period/Deductions |  | (402) | (172)
Contract liabilities at end of period |  | 4,925 | 6,328
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 5,327 | 0
Contract liabilities at end of period |  | 4,925 | 6,328
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca |  |  |
Deferred Revenue, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 52,677 | 63,211
Contract liabilities at end of period |  | 52,149 | 56,058
Collaboration Liabilities, Roll Forward [Abstract] |  |  |
Contract liabilities at beginning of period |  | 52,677 | 63,211
Additions |  | 1,891 | 283
Deductions |  | (2,419) | (7,436)
Contract liabilities at end of period |  | € 52,149 | € 56,058

X
- References No definition available. + Details
Name: | ifrs-full_ContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Liabilities, Roll Forward + References No definition available. + Details
Name: | inpha_CollaborationLiabilitiesRollForwardAbstract
Namespace Prefix: | inpha_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The decrease in contract liabilities resulting from deductions. + References No definition available. + Details
Name: | inpha_DecreaseThroughDeductionsContractLiabilities
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Deferred Revenue, Roll Forward + References No definition available. + Details
Name: | inpha_DeferredRevenueRollForwardAbstract
Namespace Prefix: | inpha_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase in contract liabilities resulting from additions. + References No definition available. + Details
Name: | inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Preclinical Molecules + References No definition available. + Details
Name: | inpha_NumberOfPreclinicalMolecules
Namespace Prefix: | inpha_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Target Options + References No definition available. + Details
Name: | inpha_NumberOfTargetOptions
Namespace Prefix: | inpha_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue From Contracts With Customers, Advance Payment Received, Research + References No definition available. + Details
Name: | inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Contracts With Customers, Advance Payment Received, Target Options + References No definition available. + Details
Name: | inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Contracts With Customers, Milestone + References No definition available. + Details
Name: | inpha_RevenueFromContractsWithCustomersMilestone
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenues From Contract Liabilities, Recognition Period, Maximum + References No definition available. + Details
Name: | inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum
Namespace Prefix: | inpha_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The decrease in contract liabilities resulting from transfer to collaboration liabilities. + References No definition available. + Details
Name: | inpha_TransferToFromCollaborationLiabilities
Namespace Prefix: | inpha_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_A2015AstraZenecaMonalizumabAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=inpha_CollaborationLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |